Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C
Identifieur interne : 001346 ( Main/Merge ); précédent : 001345; suivant : 001347Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C
Auteurs : M. Motavaf [Iran] ; S. Safari [Iran] ; S. M. Alavian [Iran]Source :
- Journal of Viral Hepatitis [ 1352-0504 ] ; 2012-11.
Abstract
Hepatitis C virus (HCV) infection remains a major cause of chronic liver disease with an estimated 170 million carriers worldwide. Current treatments have significant side effects and have met with only partial success. Therefore, alternative antiviral drugs that efficiently block virus production are needed. During recent decades, RNA interference (RNAi) technology has not only become a powerful tool for functional genomics but also represents a new therapeutic approach for treating human diseases including viral infections. RNAi is a sequence‐specific and post‐transcriptional gene silencing process mediated by double‐stranded RNA (dsRNA). As the HCV genome is a single‐stranded RNA that functions as both a messenger RNA (mRNA) and replication template, it is an attractive target for the study of RNAi‐based viral therapies. In this review, we will give a brief overview about the history and current status of RNAi and focus on its potential application as a therapeutic option for treatment for HCV infection.
Url:
DOI: 10.1111/jvh.12006
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000758
- to stream Istex, to step Curation: 000725
- to stream Istex, to step Checkpoint: 000059
Links to Exploration step
ISTEX:CE9BD7C3C4B68967407111DE0FB7BABBFE22F1C8Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C</title>
<author><name sortKey="Motavaf, M" sort="Motavaf, M" uniqKey="Motavaf M" first="M." last="Motavaf">M. Motavaf</name>
</author>
<author><name sortKey="Safari, S" sort="Safari, S" uniqKey="Safari S" first="S." last="Safari">S. Safari</name>
</author>
<author><name sortKey="Alavian, S M" sort="Alavian, S M" uniqKey="Alavian S" first="S. M." last="Alavian">S. M. Alavian</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CE9BD7C3C4B68967407111DE0FB7BABBFE22F1C8</idno>
<date when="2012" year="2012">2012</date>
<idno type="doi">10.1111/jvh.12006</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-QPQ7QW60-4/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000758</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000758</idno>
<idno type="wicri:Area/Istex/Curation">000725</idno>
<idno type="wicri:Area/Istex/Checkpoint">000059</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000059</idno>
<idno type="wicri:doubleKey">1352-0504:2012:Motavaf M:therapeutic:potential:of</idno>
<idno type="wicri:Area/Main/Merge">001346</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C</title>
<author><name sortKey="Motavaf, M" sort="Motavaf, M" uniqKey="Motavaf M" first="M." last="Motavaf">M. Motavaf</name>
<affiliation wicri:level="1"><country xml:lang="fr">Iran</country>
<wicri:regionArea>Tehran Hepatitis Center (THC), Tehran</wicri:regionArea>
<wicri:noRegion>Tehran</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Safari, S" sort="Safari, S" uniqKey="Safari S" first="S." last="Safari">S. Safari</name>
<affiliation wicri:level="1"><country xml:lang="fr">Iran</country>
<wicri:regionArea>Tehran Hepatitis Center (THC), Tehran</wicri:regionArea>
<wicri:noRegion>Tehran</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Iran</country>
<wicri:regionArea>Department of Anesthesiology and Pain Medicine, Tehran University of Medical Sciences, Tehran</wicri:regionArea>
<wicri:noRegion>Tehran</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Alavian, S M" sort="Alavian, S M" uniqKey="Alavian S" first="S. M." last="Alavian">S. M. Alavian</name>
<affiliation wicri:level="1"><country xml:lang="fr">Iran</country>
<wicri:regionArea>Tehran Hepatitis Center (THC), Tehran</wicri:regionArea>
<wicri:noRegion>Tehran</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Iran</country>
<wicri:regionArea>Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences and Tehran Hepatitis Center, Tehran</wicri:regionArea>
<wicri:noRegion>Tehran</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Iran</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Journal of Viral Hepatitis</title>
<title level="j" type="alt">JOURNAL OF VIRAL HEPATITIS</title>
<idno type="ISSN">1352-0504</idno>
<idno type="eISSN">1365-2893</idno>
<imprint><biblScope unit="vol">19</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="757">757</biblScope>
<biblScope unit="page" to="765">765</biblScope>
<biblScope unit="page-count">9</biblScope>
<date type="published" when="2012-11">2012-11</date>
</imprint>
<idno type="ISSN">1352-0504</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1352-0504</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Hepatitis C virus (HCV) infection remains a major cause of chronic liver disease with an estimated 170 million carriers worldwide. Current treatments have significant side effects and have met with only partial success. Therefore, alternative antiviral drugs that efficiently block virus production are needed. During recent decades, RNA interference (RNAi) technology has not only become a powerful tool for functional genomics but also represents a new therapeutic approach for treating human diseases including viral infections. RNAi is a sequence‐specific and post‐transcriptional gene silencing process mediated by double‐stranded RNA (dsRNA). As the HCV genome is a single‐stranded RNA that functions as both a messenger RNA (mRNA) and replication template, it is an attractive target for the study of RNAi‐based viral therapies. In this review, we will give a brief overview about the history and current status of RNAi and focus on its potential application as a therapeutic option for treatment for HCV infection.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001346 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001346 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= CovidV2 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:CE9BD7C3C4B68967407111DE0FB7BABBFE22F1C8 |texte= Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |